Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection

Journal of Infectious Diseases

Volumn 191, Issue 7, 2005, Pages 1169-1179

  Lascar, R Monica ^a   Lopes, A Ross ^a   Gilson, Richard J ^a   Dunn, Claire ^a   Johnstone, Ruth ^a   Copas, Andrew ^a   Reignat, Stephanie ^a   Webster, George ^a   Bertoletti, Antonio ^a   Maini, Mala K ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Windeyer Institute of Medical Sciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DIDANOSINE; EFAVIRENZ; GAMMA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; EPITOPES; HEPATITIS B; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; LONGITUDINAL STUDIES; MALE; VIRAL PROTEINS;

EID: 20144385097     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428502     Document Type: Article

References (42)

1. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-6.
2. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-7.
3. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-71.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
5. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163:454-9.
6. Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992; 117:837-8.
7. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
8. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11:597-606.
9. + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77:68-76.
10. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191:1269-80.
11. Penna A, Artini M, Cavalli A, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-94.
12. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104-8.
13. Francisci D, Baldelli F, Papili R, Stagni G, Pauluzzi S. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur J Epidemiol 1995; 11:123-6.
14. Penna A, Chisari FV, Bertoletti A, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174:1565-70.
15. Nayersina R, Fowler P, Guilhot S, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150:4659-71.
16. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:1047-58.
17. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76:2634-40.
18. + responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol 1999; 73:7108-16.
19. + T cells. Eur J Immunol 2002; 32:1080-9.
20. Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. J Infect Dis 2003; 188:1815-9.
21. Day CL, Walker BD. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003; 198:1773-7.
22. + T cells associated with the control of infection. Gastroenterology 1999; 117:1386-96.
23. Chazouilleres O, Mamish D, Kim M, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142-6.
24. Waite J, Gilson RJ, Weller IV, et al. Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 1988; 2:443-8.
25. Komanduri KV, Donahoe SM, Moretto WJ, et al. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology 2001; 279:459-70.
26. + T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001; 98:146-55.
27. Xu XN, Screaton GR, McMichael AJ. Virus infections: escape, resistance, and counterattack. Immunity 2001; 15:867-70.
28. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998; 395:189-94.
29. Selin LK, Lin MY, Kraemer KA, et al. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 1999; 11:733-42.
30. McNally JM, Zarozinski CC, Lin MY, Brehm MA, Chen HD, Welsh RM. Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J Virol 2001; 75:5965-76.
31. + T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J Virol 2000; 74:4127-38.
32. + T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 2001; 75:6508-16.
33. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4:953-6.
34. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy, prospective cohort study. Swiss HIV Cohort Study. BMJ 1999; 319:23-4.
35. Havlir DV, Schrier RD, Torriani FJ, Chervenak K, Hwang JY, Boom WH. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis 2000; 182:1658-63.
36. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199-204.
37. + T cells endowed with proliferative capacity. J Exp Med 2003; 198:1909-22.
38. Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39:595-605.
39. + T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001; 13:483-8.
40. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999; 180:1050-6.
41. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-75.
42. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33:963-71.